Alphatec Holdings (ATEC) Stock Overview
A medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ATEC from our risk checks.
ATEC Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alphatec Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.31 |
| 52 Week High | US$23.29 |
| 52 Week Low | US$6.82 |
| Beta | 0.86 |
| 1 Month Change | 1.09% |
| 3 Month Change | 23.80% |
| 1 Year Change | -37.81% |
| 3 Year Change | -37.52% |
| 5 Year Change | -27.94% |
| Change since IPO | -91.36% |
Recent News & Updates
Seeking Alpha • 15h
Alphatec: Straightening Its Back
Summary Alphatec reports 15% revenue growth and improved operating leverage, with realistic break-even levels approaching despite ongoing net losses and dilution. Alphatec maintains $882 million in sales guidance and raises adjusted EBITDA guidance to $140 million, signaling confidence in margin improvements and operational progress. Leverage concerns are easing as free cash flow turns positive, dilution slows, and interest expenses decline, aided by strong EOS imaging technology growth. Trading at just over 2x sales, Alphatec offers speculative appeal given robust growth, margin gains, and a significant discount to peer multiples. Read the full article on Seeking Alpha
Narrative Update • Aug 05
ATEC: 2026 Revenue Mix Will Support Constructive Upside Case
Analysts have adjusted their price target on Alphatec Holdings from $24.00 to about $22.41. The change reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E estimates.Recent updates
Seeking Alpha • 15h
Alphatec: Straightening Its Back
Summary Alphatec reports 15% revenue growth and improved operating leverage, with realistic break-even levels approaching despite ongoing net losses and dilution. Alphatec maintains $882 million in sales guidance and raises adjusted EBITDA guidance to $140 million, signaling confidence in margin improvements and operational progress. Leverage concerns are easing as free cash flow turns positive, dilution slows, and interest expenses decline, aided by strong EOS imaging technology growth. Trading at just over 2x sales, Alphatec offers speculative appeal given robust growth, margin gains, and a significant discount to peer multiples. Read the full article on Seeking AlphaNarrative Update • Aug 05
ATEC: 2026 Revenue Mix Will Support Constructive Upside Case
Analysts have adjusted their price target on Alphatec Holdings from $24.00 to about $22.41. The change reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E estimates.
Narrative Update • Jul 20
ATEC: 2026 Surgical Revenue Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target for Alphatec Holdings from $17.33 to $16.00, citing updated fair value estimates, a slightly lower discount rate, and an adjusted future P/E assumption that reflects a more measured approach to valuation multiples. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, providing investors with updated expectations for the business.Narrative Update • Jul 06
ATEC: 2026 Revenue Outlook Will Support Constructive Upside Case
Analysts have trimmed their price target for Alphatec Holdings to $24.00 from $28.00, reflecting updated assumptions for revenue growth, profit margins, the discount rate, and the future P/E multiple. What's in the News for Alphatec Holdings Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $882 million.
Narrative Update • Jun 22
ATEC: Legal Overhang And 2026 Outlook Will Support Future Upside
Analysts have maintained their $11.00 price target for Alphatec Holdings, citing updated model assumptions that reflect slightly adjusted discount rates, revenue growth expectations, profit margins, and future P/E estimates. What’s in the News for Alphatec Holdings Schall Law Firm has begun an investigation into Alphatec Holdings, Inc.Narrative Update • Jun 05
ATEC: New Bank Facility And 2026 Outlook Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $20.00 to $11.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue growth of 17% and total revenue growth of 14%, according to recent earnings coverage (source: Alphatec Reports Strong Q1 2026 Growth and Secures New Bank Facility).Narrative Update • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).Narrative Update • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.Narrative Update • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.Narrative Update • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).Narrative Update • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Narrative Update • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Narrative Update • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).Narrative Update • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).Narrative Update • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Analysis Article • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...Narrative Update • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.Narrative Update • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.Narrative Update • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).Narrative Update • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.Narrative Update • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Analysis Article • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...Narrative Update • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Analysis Article • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...Analysis Article • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...New Narrative • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Analysis Article • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...Analysis Article • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...Analysis Article • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...Analysis Article • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking AlphaAnalysis Article • Nov 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shareholders would be excited to see that the share price has had a great...Shareholder Returns
| ATEC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.2% | 1.6% | 3.5% |
| 1Y | -37.8% | -12.6% | 20.5% |
Return vs Industry: ATEC underperformed the US Medical Equipment industry which returned -12.6% over the past year.
Return vs Market: ATEC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATEC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATEC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Alphatec Holdings, Inc. Fundamentals Summary
| ATEC fundamental statistics | |
|---|---|
| Market cap | US$1.42b |
| Earnings (TTM) | -US$109.99m |
| Revenue (TTM) | US$815.05m |
1.8x
P/S Ratio-13.1x
P/E RatioIs ATEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATEC income statement (TTM) | |
|---|---|
| Revenue | US$815.05m |
| Cost of Revenue | US$237.69m |
| Gross Profit | US$577.37m |
| Other Expenses | US$687.36m |
| Earnings | -US$109.99m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 70.84% |
| Net Profit Margin | -13.50% |
| Debt/Equity Ratio | 4,991.8% |
How did ATEC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 22:08 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alphatec Holdings, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Caitlin Cronin | Canaccord Genuity |